SG301-SC / Sumgen Biotech - LARVOL DELTA

SG301-SC Injection Safety Study in Subjects With Systemic Lupus Erythematosus (clinicaltrials.gov) - P1 | N=48 | Completed | Sponsor: Hangzhou Sumgen Biotech Co., Ltd. | Active, not recruiting ➔ Completed | Trial completion date: Oct 2026 ➔ Jan 2026

IO biomarker • Trial completion • Trial completion date • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

SG301-SC Injection Safety Study in Subjects With Primary ITP Patients (clinicaltrials.gov) - P2 | N=60 | Recruiting | Sponsor: Hangzhou Sumgen Biotech Co., Ltd.

New P2 trial • Hematological Disorders • Immune Thrombocytopenic Purpura • Thrombocytopenia • Thrombocytopenic Purpura

To Evaluate the Efficacy and Safety of SG301 SC Injection in Systemic Lupus Erythematosus (clinicaltrials.gov) - P2 | N=120 | Recruiting | Sponsor: Hangzhou Sumgen Biotech Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

SG301-SC Injection Safety Study in Subjects With Systemic Lupus Erythematosus (clinicaltrials.gov) - P1 | N=48 | Active, not recruiting | Sponsor: Hangzhou Sumgen Biotech Co., Ltd. | Recruiting ➔ Active, not recruiting | Trial primary completion date: May 2026 ➔ Jan 2026

Enrollment closed • IO biomarker • Trial primary completion date • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

To Evaluate the Efficacy and Safety of SG301 SC Injection in Systemic Lupus Erythematosus (clinicaltrials.gov) - P2 | N=120 | Not yet recruiting | Sponsor: Hangzhou Sumgen Biotech Co., Ltd.

New P2 trial • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

A Study of Anti-CD38 Monoclonal Antibody (SG301) Subcutaneous Injection in Children With Nephrotic Syndrome With Frequent Relapses or Steroid Dependence (clinicaltrials.gov) - P2 | N=30 | Recruiting | Sponsor: Mao Jianhua | Not yet recruiting ➔ Recruiting

Enrollment open • Glomerulonephritis • Nephrology • Renal Disease

A Study of Anti-CD38 Monoclonal Antibody (SG301) Subcutaneous Injection in Children With Nephrotic Syndrome With Frequent Relapses or Steroid Dependence (clinicaltrials.gov) - P2 | N=30 | Not yet recruiting | Sponsor: Mao Jianhua

New P2 trial • Glomerulonephritis • Nephrology • Renal Disease

A Clinical Study to Evaluate the Preliminary Efficacy and Safety of SG301 SC Subcutaneous Injection in Children with Frequently Relapsing or Steroid-Dependent Nephrotic Syndrome (ChiCTR) - P=N/A | N=30 | Not yet recruiting | Sponsor: Children's Hospital,Zhejiang University School of Medicine; Children's Hospital,Zhejiang University School of Medicine

New trial • Glomerulonephritis • Nephrology • Renal Disease

SG301-SC Injection Safety Study in Subjects With Systemic Lupus Erythematosus (clinicaltrials.gov) - P1 | N=48 | Recruiting | Sponsor: Hangzhou Sumgen Biotech Co., Ltd. | Trial completion date: Oct 2025 ➔ Oct 2026 | Trial primary completion date: May 2025 ➔ May 2026

IO biomarker • Trial completion date • Trial primary completion date • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus